ReviewHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme2020
Updates on the Management of Thyroid Cancer.
Review in Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 156 citations in OpenAlex.
- Thyroid and renal cancers: A bidirectional association.Frontiers in oncology · 2022Pooled it
- Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review.Computational and mathematical methods in medicine · 2022Pooled it
- A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2022Trial
- Influencing factors and prediction model of ultrasound-based false-negative central lymph node metastasis in localized papillary thyroid carcinoma.Gland surgery · 2026Article
- Integrative Bioinformatics Analysis Reveals COL13A1 and COL23A1 as Potential Diagnostic and Prognostic Biomarkers in Thyroid Cancer.Health science reports · 2026Article
- The SUMO specific peptidase SENP3 promotes papillary thyroid cancer progression by deSUMOylation of SETDB1 and regulating GLI2 transcription.Clinical and experimental medicine · 2026Article
- Characterization of the patient profile and efficacy of empirical radioiodine therapy in differentiated thyroid cancer with biochemical evidence without identified iodine-avid structural metastatic disease.Endocrine connections · 2026Article
- Individualized survival prediction in medullary thyroid carcinoma using a least absolute shrinkage and selection operator-Cox-based nomogram.The Journal of international medical research · 2026Article
- Risk factors and predictive nomograms for early mortality in patients with thyroid cancer lung metastasis based on the SEER database and a Chinese population study.Gland surgery · 2025Article
- Real-world clinical experience of reduced-dose initiation of lenvatinib in Japanese patients with radioiodine-refractory differentiated thyroid cancer.Endocrine journal · 2025Article
- The predictive value of thyroid hormone sensitivity parameters for cervical lymph node metastasis in patients with differentiated thyroid cancer.Annals of medicine · 2025Article
- Mechanism of METTL14-mediated RAD21 mRNA epigenetic transcriptome modification in inhibiting thyroid cancer development.World journal of surgical oncology · 2025Article
- Overexpressed MET drives aggressive thyroid cancer phenotypes and serves as a precision therapeutic target.Scientific reports · 2025Article
- Genetic variations in amino acid metabolism-related genes are associated with risk of papillary thyroid carcinoma: a case-control study.BMC endocrine disorders · 2025Article
- Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus.European thyroid journal · 2025Review
- Tumor Volume Doubling Time of Less Than 1 Year Is Associated With a Higher Risk of Death From Medullary Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2025Article
- Polyamine Metabolism Promotes the Progression of Thyroid Carcinoma by Regulating the Immune Phenotype of Tumor Associated Macrophages.Smart medicine · 2025Article
- RNA‑seq analysis of predictive markers associated with glutamine metabolism in thyroid cancer.Molecular medicine reports · 2025Article
- Exploring the Public Awareness of Thyroid Cancer in Northern Saudi Arabia: A Preliminary Stage for Health Promotion.Healthcare (Basel, Switzerland) · 2025Article
- Upregulation ofInternational journal of molecular sciences · 2025Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The diagnostic modalities, stratification tools, and treatment options for patients with thyroid cancer have rapidly evolved since the development of the American Thyroid Association (ATA) guidelines in 2015. This review compiles newer concepts in diagnosis, stratification tools and treatment options for patients with differentiated thyroid cancer (DTC), medullary thyroid carcinoma (MTC) and anaplastic thyroid cancer (ATC). Newer developments apply precision medicine in thyroid cancer patients to avoid over-treatment in low risk disease and under-treatment in high risk disease. Among novel patient-tailored therapies are selective RET inhibitors that have shown efficacy in the treatment of MTC with limited systemic toxicity compared with non-specific tyrosine kinase inhibitors. The combination of BRAF and MEK inhibitors have revolutionized management of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.